Iambic Therapeutics filed a registration statement for an initial public offering of its common stock, according to a filing with the US Securities and Exchange Commission on Monday.

Underwriters have been granted a 30-day option to purchase additional shares.

Terms of the offering, including the number of shares and expected price range, were not yet disclosed.

The company has applied to list its shares on the Nasdaq Global Select Market under the symbol "IAM."